5mg/片，60片/盒。 【禁忌症】 无。 【警告和预防措施】 • 已经观察到高血压，包括高血压危象。在开始使用LuciAxi之前，应控制好血压。监测高血压并根据需要进行治疗。对于使用抗高血 …

2024年8月14日 · Apixaban is used to lower the risk of stroke caused by a blood clot in people with a heart rhythm disorder called atrial fibrillation. Apixaban is also used after hip or knee …

KEYNOTE-426研究(NCT02853331)是一项随机、开放标签、3期试验，在首个中期分析中，一线治疗帕博利珠单抗（pembro）+阿昔替尼（axi）显示，与舒尼替尼（sun）相比，晚期ccRCC …

2022年6月7日 · 肾癌围手术期治疗一直是临床研究的热点，2021年ASCO会议公布的KEYNOTE564研究证实了免疫治疗在高危肾癌术后辅助治疗取得成功，本次会议除了该项临 …

2018年6月1日 · Axitinib (Axi) is a VEGF-R inhibitor with prior clinical data supporting increased efficacy with dose titration. The existing titration schema of 5mg BID to 7mg BID to 10mg BID …

2025年2月18日 · Most patients (95%; n=285) started AXI at the initial recommended dose of 5 mg twice daily (BID; Table). Few patients (14.3%; n=43) required AXI dose reductions, with a …

2023年6月7日 · Methods: Adults with confirmed locally advanced or metastatic ccRCC with or without sarcomatoid features, no previous systemic therapy for metastatic ccRCC, KPS ≥70%, …

The starting dose of axitinib was 5 mg twice daily, with a possibility of titration to 7 mg twice daily, and then 10 mg twice daily as per the previously described criteria in the AXIS trial. The fixed …

Keynote-426研究结果更新Keynote-426研究中期报告显示了Pembrolizumab+Axitinib的组合作为一线治疗方案显著改善了转移性肾癌患者的预后。 此次报告更新结果。 上海交通大学医学院附 …

2020年5月15日 · 结论：帕博利珠单抗+阿昔替尼用于aRCC患者的一线治疗，在中位随访时间为27个月时，相对于舒尼替尼持续表现出更佳的抗肿瘤活性。 编辑丨中国医学论坛报 佑明. …

Co-stimulatory PFOX activates exhausted T-cells, and dendritic cells and increases proliferation, effector function, and survival of T cells. We hypothesized that PFOX + Axi would improve …

Here, we report long-term efficacy and safety data of the combination AXI/pembro from the Phase 1 trial, with almost 5 years of follow-up. Methods: 52 treatment-naïve patients with advanced …

Co-stimulatory PFOX activates exhausted T-cells, and dendritic cells and increases proliferation, effector function, and survival of T cells. We hy-pothesized that PFOX + Axi would improve …

2024年7月25日 · 5 mg orally 2 times a day Use: Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Adult Dose for Deep Vein Thrombosis:

Axitinib (Axi) is an orally available tyrosine kinase inhibitor which is approved for the treatment of metastatic renal cell carcinoma. It has a high affinity and specificity for vascular endothelial …

2023年2月21日 · In 11% of pts a starting dose of Axi <5mg was reported (8% higher starting dose). 2% of pts experienced Axi dose titration while 37% of pts had a dose reduction. Pts …

We report long-term efficacy and safety of the axitinib/pembrolizumab from the phase I trial (NCT02133742), after 46-55 months from study initiation (data cut-off date, 23rd July 2019). …

2023年2月20日 · In 11% of pts a starting dose of Axi <5mg was reported (8% higher starting dose). 2% of pts experienced Axi dose titration while 37% of pts had a dose reduction. Pts …

Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC). …

Background: In KEYNOTE-426, pembro + axi significantly improved OS (HR 0.53, P < .0001), PFS (HR 0.69, P = .0001), and ORR (59.3% vs 35.7%, P < .0001) vs sunitinib and had …